



12-24-03

1648 \$

Express Mail No.: EV335858129US

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

Application of: Young et al.

Confirmation No.: 5866

Application No.: 09/996,288

Group Art Unit: 1648

Filed: November 28, 2001

Examiner: Chen, Stacy B.

For: METHODS OF ADMINISTERING/
DOSING ANTI-RSV ANTIBODIES
FOR PROPHYLAXIS AND
TREATMENT

Attorney Docket No.: 10271-047

SUPPLEMENTAL INFORMATION DISCLOSURE STATEMENT
UNDER 37 C.F.R. §1.56 AND §1.97

Commissioner for Patents
P.O. Box 1450
Alexandria, VA 22313-1450

Sir:

In accordance with the duty of disclosure imposed by 37 C.F.R. § 1.56 and § 1.97 to inform the Patent Office of all references coming to the attention of each individual associated with the filing or prosecution of the subject application, which are or may be material to the patentability of any claim of the application, Attorneys for Applicants hereby invite the Examiner's attention to the references **DL-DT** listed on the attached revised form PTO 1449 entitled "List of References Cited by Applicant." Copies of references DL-DT are submitted herewith.

Identification of the listed references is not meant to be construed as an admission of Applicants or Attorneys for Applicants that such references are available as "prior art" against the subject application. Consequently, Applicants respectfully decline to use form PTO-1449, since this form identifies all of the references cited therein as "Prior Art." As an alternative, Applicants submit herewith a "revised form PTO 1449" entitled "List of References Cited" instead of "List of Prior Art Cited."

Applicants respectfully request that the Examiner review the foregoing references and that the references be made of record in the file history of the application.



Pursuant to 37 C.F.R. § 1.97(c) and 1.17(p), Applicants estimate that the fee due in connection with this Information Disclosure Statement is \$180.00. Please charge any required fee to Pennie & Edmonds Deposit Account No. 16-1150. A duplicate of this sheet is enclosed for accounting purposes.

Respectfully submitted,

Date December 22, 2003

Anthony M. Insogna 35,203
Anthony M. Insogna (Reg. No.)

PENNIE & EDMONDS LLP
1155 Avenue of the Americas
New York, New York 10036-2711
(212) 790-9090

Enclosures

By: Jennifer J. Chheola
Reg No. 46,617

**LIST OF REFERENCES CITED BY APPLICANT**
(Use several sheets if necessary)

ATTY DOCKET NO.

10271-047

APPLICATION NO

09/996,288

APPLICANT

Young et al.

FILING DATE

November 28, 2001

GROUP

1648

U.S. PATENT DOCUMENTS

*EXAMINER INITIAL	DOCUMENT NUMBER	DATE	NAME	CLASS	SUBCLASS	FILING DATE IF APPROPRIATE
DL	5,939,068	8/17/99	Brams et al.			

FOREIGN PATENT DOCUMENTS

DOCUMENT NUMBER	DATE	COUNTRY	CLASS	SUBCLASS	TRANSLATION
					YES NO
DM	WO 96/05229	2/22/96	PCT		

OTHER REFERENCES (Including Author, Title, Date, Pertinent Pages, Etc.)

DN	Hacking et al., 2002, "Respiratory syncytial virus - viral biology and the host response," J. Infection 45:18-24
DO	Heard et al., 1999, "Two neutralizing human RSV antibodies: cloning, expression, and characterization," Mol. Med. 5:35-45
DP	Landry et al., "Evaluation of reconstituted lophilized palivizumab given intravenously at 15 and 30 mg/kg," Poster Session, Tuesday, Infect. Dis. 166A: 969
DQ	Saez-Llorens et al., 1997, "Phase I/II open label multi dose escalation trial of a humanized respiratory syncytial virus (RSV) monoclonal antibody (Medi-493) administered intramuscularly (IM) in high risk children," Abstracts in Non HIV virology, ICAAC Toronto
DR	Subramanian et al., 1997, "Randomized double blind placebo controlled dose escalation trial of a humanized respiratory syncytial virus monoclonal antibody in high risk infants," Poster session infect. dis. 130A:768
DS	Sorbera et al., 1998, "Palivizumab," Drugs of the Future 23:970-976
DT	Sorbera et al., 1998, "Palivizumab," Drugs Data Report 20:702-703

EXAMINER

DATE CONSIDERED

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

LIST OF REFERENCES CITED BY APPLICANT

(Use several sheets if necessary)

ATTY DOCKET NO.

10271-047

APPLICATION NO

09/996,288

APPLICANT

Young et al.

FILING DATE

November 28, 2001

GROUP

1648

U.S. PATENT DOCUMENTS

*EXAMINER INITIAL		DOCUMENT NUMBER	DATE	NAME	CLASS	SUBCLASS	FILING DATE IF APPROPRIATE
	DL	5,939,068	8/17/99	Brams et al.			

FOREIGN PATENT DOCUMENTS

		DOCUMENT NUMBER	DATE	COUNTRY	CLASS	SUBCLASS	TRANSLATION	
							YES	NO
	DM	WO 96/05229	2/22/96	PCT				

OTHER REFERENCES (Including Author, Title, Date, Pertinent Pages, Etc.)

DN	Hacking et al., 2002, "Respiratory syncytial virus - viral biology and the host response," J. Infection 45:18-24
DO	Heard et al., 1999, "Two neutralizing human RSV antibodies: cloning, expression, and characterization," Mol. Med. 5:35-45
DP	Landry et al., "Evaluation of reconstituted lophilized palivizumab given intravenously at 15 and 30 mg/kg," Poster Session, Tuesday, Infect. Dis. 166A: 969
DQ	Saez-Llorens et al., 1997, "Phase I/II open label multi dose escalation trial of a humanized respiratory syncytial virus (RSV) monoclonal antibody (Medi-493) administered intramuscularly (IM) in high risk children," Abstracts in Non HIV virology, ICAAC Toronto
DR	Subramanian et al., 1997, "Randomized double blind placebo controlled dose escalation trial of a humanized respiratory syncytial virus monoclonal antibody in high risk infants," Poster session infect. dis. 130A:768
DS	Sorbera et al., 1998, "Palivizumab," Drugs of the Future 23:970-976
DT	Sorbera et al., 1998, "Palivizumab," Drugs Data Report 20:702-703

EXAMINER

DATE CONSIDERED

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.